Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620583
Title:
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
Authors:
Thwaites, G. E.; Scarborough, M.; Szubert, A.; Nsutebu, E.; Tilley, R.; Greig, J.; Wyllie, S. A.; Wilson, P.; Auckland, Cressida; Cairns, J.; Ward, D.; Lal, P.; Guleri, A.; Jenkins, N.; Sutton, J.; Wiselka, M.; Armando, G-R; Graham, C.; Chadwick, P. R.; Barlow, G.; Gordon, N. C.; Young, B.; Meisner, S.; McWhinney, P.; Price, D. A.; Harvey, D.; Nayar, D.; Jeyaratnam, D.; Planche, T.; Minton, J.; Hudson, F.; Hopkins, S.; Williams, J.; Török, M. E.; Llewelyn, M. J.; Edgeworth, J. D.; Walker, A. S.
Abstract:
Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection.
Citation:
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. 2017 Lancet
Publisher:
Elsevier
Journal:
Lancet
Issue Date:
14-Dec-2017
URI:
http://hdl.handle.net/11287/620583
DOI:
10.1016/S0140-6736(17)32456-X
PubMed ID:
29249276
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(17)32456-X
Note:
This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.
Type:
Journal Article; Multicenter Study; Randomized Controlled Trial
Language:
en
ISSN:
1474-547X
Appears in Collections:
Exeter Clinical Laboratory International (Blood Sciences, Genetics, Cellular Pathology & Microbiology); 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThwaites, G. E.en
dc.contributor.authorScarborough, M.en
dc.contributor.authorSzubert, A.en
dc.contributor.authorNsutebu, E.en
dc.contributor.authorTilley, R.en
dc.contributor.authorGreig, J.en
dc.contributor.authorWyllie, S. A.en
dc.contributor.authorWilson, P.en
dc.contributor.authorAuckland, Cressidaen
dc.contributor.authorCairns, J.en
dc.contributor.authorWard, D.en
dc.contributor.authorLal, P.en
dc.contributor.authorGuleri, A.en
dc.contributor.authorJenkins, N.en
dc.contributor.authorSutton, J.en
dc.contributor.authorWiselka, M.en
dc.contributor.authorArmando, G-Ren
dc.contributor.authorGraham, C.en
dc.contributor.authorChadwick, P. R.en
dc.contributor.authorBarlow, G.en
dc.contributor.authorGordon, N. C.en
dc.contributor.authorYoung, B.en
dc.contributor.authorMeisner, S.en
dc.contributor.authorMcWhinney, P.en
dc.contributor.authorPrice, D. A.en
dc.contributor.authorHarvey, D.en
dc.contributor.authorNayar, D.en
dc.contributor.authorJeyaratnam, D.en
dc.contributor.authorPlanche, T.en
dc.contributor.authorMinton, J.en
dc.contributor.authorHudson, F.en
dc.contributor.authorHopkins, S.en
dc.contributor.authorWilliams, J.en
dc.contributor.authorTörök, M. E.en
dc.contributor.authorLlewelyn, M. J.en
dc.contributor.authorEdgeworth, J. D.en
dc.contributor.authorWalker, A. S.en
dc.date.accessioned2017-12-29T10:47:12Z-
dc.date.available2017-12-29T10:47:12Z-
dc.date.issued2017-12-14-
dc.identifier.citationAdjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. 2017 Lanceten
dc.identifier.issn1474-547X-
dc.identifier.pmid29249276-
dc.identifier.doi10.1016/S0140-6736(17)32456-X-
dc.identifier.urihttp://hdl.handle.net/11287/620583-
dc.description.abstractStaphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0140-6736(17)32456-Xen
dc.rightsArchived with thanks to Lancet (London, England). This is an Open Access article under the CC BY 4.0 license.en
dc.subjectWessex Classification Subject Headings::Microbiology. Immunologyen
dc.titleAdjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.en
dc.typeJournal Articleen
dc.typeMulticenter Studyen
dc.typeRandomized Controlled Trialen
dc.identifier.journalLanceten
dc.description.noteThis article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.en
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.